High Frequency of CYP2C19*3 Heterozygotes Among Patients Under Clopidogrel Treatment in Ouagadougou, Burkina Faso.

<b>Background and Objective:</b> Despite its widespread use in cardiology, patient's response to clopidogrel exhibits significant interindividual variability, often leading to persistent thromboembolic complications. The hepatic Cytochrome P450 2C19 (CYP2C19) superfamily plays a pivotal role in clopidogrel's conversion to its active form and CYP2C19 polymorphisms significantly contribute to this variability. This study aimed to evaluate the prevalence and impact of the CYP2C19 rs4986893 polymorphism on clopidogrel treatment response. <b>Materials and Methods:</b> Seventy-three patients with Cardiovascular Diseases (CVD) undergoing clopidogrel antiplatelet therapy for a minimum of six months were recruited from Centre Hospitalier Universitaire Yalgado Ouédraogo (CHU-YO). Sociodemographic data were collected and DNA was extracted from blood samples for CYP2C19 rs4986893 genotyping using PCR-RFLP. <b>Results:</b> The patient's mean age was 62.56±13.45 years, ranging from 23 to 94 years, with a male-to-female sex ratio of 1.28. Most patients came from the informal sector, primarily of Mossi ethnicity and residing in Ouagadougou. Acute coronary syndromes (ACS) and hypertension were the predominant reasons for consultation, with clopidogrel showing efficacy in 97.3% of cases. While 72.6% had no family history of CVD, hypertension was prevalent among those with familial cardiovascular conditions. Genetic analysis revealed a 65.8% frequency of heterozygotes CYP2C19*1/*3, with no mutant homozygotes CYP2C19*3/*3 detected. The results of the present study underscore a high prevalence of heterozygotes CYP2C19*1/*3 among patients with cardiovascular diseases. <b>Conclusion:</b> This intermediate metabolic phenotype, along with a good response to clopidogrel, suggests that CYP2C19*1/*3 genotype promotes a favourable response to clopidogrel therapy.

Le magnésium et le calcium réduisent la sévérité des troubles de la mémoire spatiale pour le modèle kaïnique d'épilepsie mésiale temporale chez la souris.

Calcium and magnesium are divalent multipotent ions playing a major role in metabolism, excitability and neuroglial plasticity. Because of these multiple properties, their deficiency induces complex brain processes leading to acute or even lasting disorders in excitability and neural networks. These ions are usually prescribed in clinical contexts of neuronal hyperexcitability such as preeclampsia and chronic stress. Our aim was to evaluate whether magnesium at 20 mg/kg and calcium at 100 mg/kg could improve the memory prognosis in the kainic model of mesial temporal epilepsy in mice. The animals were organized into 6 groups: control group (without kainate), reference group (GR) without administration of ions, groups treated with magnesium or calcium from the third day (respectively G1m, G1c), groups treated with magnesium or calcium from the third week (respectively G2m, G2c). The mice treated by ions performed better than GR mice, but magnesium was more effective. Memory (short term-long term) was differently affected by kainate or improved by magnesium-calcium. In addition, magnesium demonstrated an increasing therapeutic effect over time while calcium had an acute and apparently decreasing action in the G1c group that received calcium early.

Le calcium et le magnésium sont des ions divalents multipotents importants pour le métabolisme, l'excitabilité, et la plasticité de la névroglie. En raison de leurs multiples propriétés, leur carence provoque des processus cérébraux complexes menant à des aberrations aigües voire durables au niveau de l'excitabilité et des réseaux neuronaux. Ces ions sont habituellement prescrits dans des contextes cliniques d'hyperexcitabilité neuronale comme la prééclampsie et le stress chronique. Notre objectif était d'évaluer si le magnésium à 20 mg/kg et le calcium à 100 mg/kg pouvaient améliorer le pronostic mnésique dans le modèle kaïnique d'épilepsie mésiale temporale chez les souris. Les animaux furent organisés en six groupes : groupe témoin (sans kaïnate), groupe de référence sans administration d'ions (GR), groupes traités au magnésium ou au calcium dès le troisième jour (respectivement G1m, G1c), groupes traités au magnésium ou au calcium à partir de la troisième semaine (respectivement G2m, G2c). Les souris traitées ont toutes présenté de meilleures performances que les souris GR, mais le magnésium était plus efficace. La mémoire (court terme­long terme) était touchée différemment par le kaïnate ou améliorée par le magnésium et le calcium. De plus, le magnésium a démontré un effet thérapeutique croissant avec le temps alors que le calcium avait un effet aigu qui semblait se dégrader pour le groupe G1c qui reçut précocement du calcium.